Oncology
Ovarian Clear Cell Carcinoma
2
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
Ovarian Clear Cell Carcinoma is an early-stage landscape with 2 programs across 2 companies. The most active players are Incyte, Lixte Biotechnology Holdings, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
8
clinical trials
Completed3 · 38%
Not yet recruiting2 · 25%
Unknown status2 · 25%
Recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07239622·36 enrolled
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Completed·—·Phase 2·NCT01824615·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)